Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826449 · ClinicalTrials.gov registry record · Phase 1
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00826449: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00826449 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00826449, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when given to patients with non-small cell lung cancer. The safety of this combination will be studied in both phases.
Primary Outcome
MTD defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Dose-limiting toxicity (DLT) defined using NCI Common Terminology Common Terminology Criteria for Adverse Events (CTCAE) version 3 as: grade 3 or higher non-hematologic toxicity (excluding initial nausea and vomiting), grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia. Grade 3-4 nausea and vomiting that cannot be controlled within 2 weeks wit
Interventions
- DRUG Dasatinib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT00826449 record still lists
NCT00826449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00826449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00826449 about?
NCT00826449 is a clinical study titled "Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)". The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when ...
What is the current status of trial NCT00826449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2009-02. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00826449?
The interventions under investigation include: Dasatinib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00826449?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00826449's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia